Reports Q1 revenue $29.38M, consensus $23.35M. “We are delighted with enrollment in our cystic fibrosis (CF) program, and the company is working diligently to provide meaningful Phase 2 interim data mid-year,” said Joseph Payne, President & CEO of Arcturus Therapeutics (ARCT). “We are encouraged by the clinical progress of our CF and OTC programs, and given the current market conditions, we made a strategic decision to streamline resources to focus on our mRNA therapeutics pipeline.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARCT:
- ARCT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Arcturus Therapeutics: Promising Developments and Strategic Partnerships Drive Buy Rating
- Arcturus Therapeutics: Promising Phase II Prospects for ARCT-032 in Cystic Fibrosis Amidst Regulatory Approvals
- Arcturus Therapeutics: Buy Rating Backed by Promising Vaccine Development and Strategic Advancements
- Arcturus Therapeutics granted fast track designation for ARCT-2304 from FDA